Incyte Corporation
http://www.incyte.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Incyte Corporation
Apellis To Try Again After EMA Rejects Geographic Atrophy Drug
The delayed decision from the CHMP is another rejection for Syfovre but Apellis still hopes the regulator may be convinced in a second review later this year.
US FDA’s Dry July? Few Goal Dates Portend Quiet Month For Approvals
Sun’s deuruxolitinib and Novo Nordisk’s insulin icodec stand out as new molecular entities among the small cluster of US FDA user fee goal dates in July.
First Nasal Adrenaline Spray Among 10 Products Heading For EU-Wide Approval
The June meeting of the European Medicines Agency's human medicines committee brought mixed fortunes for companies. 10 new products were recommended for pan-EU approval, two drugs were rejected, while the conditional approval of one drug is set to be revoked. PTC Therapeutics again faced disappointment regarding its Duchenne muscular dystrophy drug Translarna, but has vowed to fight back.
US Rejected Drug Odronextamab Among 11 EU Marketing Hopefuls
Regeneron, whose blood cancer treatment odronextamab was recently turned down by the US regulator but not for reasons relating to efficacy or safety, could soon learn whether its product will be among the drugs to get the thumbs up from the CHMP, the European Medicines Agency’s human medicines committee.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Maxia Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice